At N-of-One, we are happy to partner with Agena Bioscience, as we are aligned in tackling complex molecular data and helping to make sense of it for the clinician,' said Chris Cournoyer, Chief Executive Officer at N-of-One, Inc.'ДЄgena's MassARRAY System is intended for Research Use Only. 'With technology like Agena's MassARRAY, clinicians have the ability to develop tests that provide robust data.В With our data interpretation expertise, we can guide pathologists and oncologists to more precise and tailored cancer treatments than ever before. 'MassARRAY Insights is part of Agena Bioscience's continued effort to support our CLIA-High Complexity Certified lab customers who are tackling the challenges presented in molecular diagnostics.В We are happy to partner with an industry leader like N-of-One to help bring our lab clients an important component that nicely follows the value of our test:В an evidence-based, clinically actionable report,' said Pete Dansky, Chief Executive Officer at Agena Bioscience.

N-of-One's long standing expertise in clinical interpretation of molecular tests in oncology aids CLIA High Complexity Labs in rapidly delivering actionable, patient-specific treatment options that are supported by the latest scientific and clinical evidence. This strategic partnership supports the expansion of Agena's recently launched MassARRAY Insights reporting network, which connects the unique capabilities of the MassARRAY with the power of high quality analysis to aid in results interpretation.

5, 2017 /PRNewswire/ - Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY В®В System.

Agena bioscience stock